ARWR250117C12000
- 0.00
- 0.000.00%
Arrowhead Pharmaceuticals Newsroom
H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $80
HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $80 Price Target
Analysts Are Bullish on Top Healthcare Stocks: Abbott Laboratories (ABT), Arrowhead Pharmaceuticals (ARWR)
Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $45
B.Riley Financial Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $51
H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $80
Arrowhead Pharmaceuticals Price Target Maintained With a $80.00/Share by HC Wainwright & Co.
Arrowhead Pharma Analyst Ratings
B.Riley Financial Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Announces Target Price $51
B. Riley Lowers Price Target on Arrowhead Pharmaceuticals to $51 From $55, Keeps Buy Rating
Chardan Capital Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $60
Promising Clinical Trial Results Boost Confidence in Arrowhead Pharmaceuticals, Justifying Buy Rating
Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $45
Analysts Offer Insights on Healthcare Companies: Biohaven Ltd. (BHVN), Arrowhead Pharmaceuticals (ARWR) and Heron Therapeutics (HRTX)
Arrowhead Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Arrowhead Pharmaceuticals Price Target Raised to $80.00/Share From $60.00 by HC Wainwright & Co.
Arrowhead Pharma Analyst Ratings
Bernstein Maintains Market Perform on Arrowhead Pharma, Lowers Price Target to $24
Analysts' Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR) and Sanofi (OtherSNYNF)
Arrowhead Pharmaceuticals Is Maintained at Neutral by Citigroup